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Abstract Skeletal injuries requiring bone augmentation tech-
niques are increasing in the context of avoiding or treating
difficult cases with bone defects, bone healing problems, and
bone regeneration limitations. Musculoskeletal severe trauma,
osteoporosis-related fractures, and conditions where bone de-
fect, bone collapse or insufficient bone regeneration occur are
prone to disability and serious complications. Bone cell ther-
apy has emerged as a promising technique to augment and
promote bone regeneration. Interest in the orthopaedic com-
munity is considerable, although many aspects related to the
research of this technique in specific indications may be
insufficiently recognised bymany orthopaedic surgeons. Clin-
ical trials are the ultimate research in real patients that may
confirm or refute the value of this new therapy. However,
before launching the required trials in bone cell therapy to-
wards bone regeneration, preclinical data is needed with the
cell product to be implanted in patients to ensure safety and
efficacy. These preclinical studies support the end-points that
need to be evaluated in clinical trials. Orthopaedic surgeons
are the ultimate players that, through their research, would
confirm in clinical trials the benefit of bone cell therapies. To
further foster this research, the pathway to eventually obtain
authorisation from the National Competent Authorities and
Research Ethics Committees under the European regulation is
reviewed, and the experience of the REBORNE European
project offers information and important clues about the cur-
rent Voluntary Harmonization Procedure and other opportu-
nities that need to be considered by surgeons and researchers
on the topic.
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Introduction
Bone healing augmentation through bone regeneration seeks
to repair or replace damaged bone, with the goal to fully
restore structure and function. While cell-based therapies are
promising new therapeutic approaches, their clinical applica-
tion is still under discussion. The burden of skeletal injuries
and bone diseases that could benefit from regenerative med-
icine approaches includes not only bone defects of traumatic
origin, but also bone healing delays and nonunions,
osteonecrotic damage, or other situations where bone regen-
eration is required but osteogenic potential is insufficient.
By using mesenchymal stem cells (MSCs), good results
have been reported for bone engineering in a number of early
clinical studies [1], most of them investigator-initiated trials
with limited scope with respect to controls and outcome. With
the implementation of a new regulatory framework for ad-
vanced therapeutic medicinal products (ATMPs) in Europe,
both the characterization of the cells and combination prod-
ucts need to be more clearly defined. Well-designed clinical
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trials (CT) are expected to clarify the safety and efficacy issues
with specific cell products in specific indications.
Significant investment has been dedicated to bone regen-
erative medicine. Although tremendous efforts have been
conducted in basic research, leading to the reinforcement of
developmental bone cell biology knowledge, very limited if
any patient benefit has been clearly obtained up-to-date. The
time of opportunities has come for clinical translation of these
advancements, and progress towards definite clinical applica-
tions might be the most genuine pathway to foster this re-
search in the benefit of our patients. The orthopaedic surgeon
requires specific information about the state of the art on
clinical applications of this therapy and ongoing research that
will soon be ready to incorporate new solutions to the ortho-
paedic armamentarium. Furthermore, the practising surgeons
need also to be aware of the opportunities and barriers to offer
their patients the best care based on the best available scien-
tific knowledge, and how to develop the required evidence
when insufficient.
Through this review, we will consider the orthopaedic bone
injuries that could constitute opportunities for bone regenera-
tion techniques, the studies that are needed to establish a well-
supported bone cell therapy through the definition of safety,
feasibility and efficacy end-points, the role of investigator-
driven clinical trials (IDCT) in advanced therapy medicinal
products for bone, and the current multinational regulatory
pathway in Europe, as followed by the REBORNE trials,
through a national approach and through the European volun-
tary harmonization procedure.
Skeletal injuries: opportunities for bone regeneration
Epidemiological reports such as the Global Burden of Disease
[2], theWHOTechnical series [3] and derived publications [4]
stress the fact that musculoskeletal conditions and bone inju-
ries are significant causes of disability worldwide.
The Bone and Joint Decade [5, 6] has contributed to focus
on the most prevalent and complex orthopaedic problems. The
conjoined efforts developed by researchers and clinicians,
institutions, and countries have increased the awareness and
the interest in the present and future solutions to these prob-
lems. Particularly, bone repair and healing advancements have
been focused through the Bone and Joint Decade on the
management of musculoskeletal trauma, the reconstruction
of osteoporosis-related fractures, and the high number of
surgically-treated spine disorders requiring fusion and
refusion.
Musculoskeletal severe trauma requires structural support
and bone healing enhancement, particularly in complex cases,
to avoid or treat bone healing complications. Especially trau-
matic bone defects associated with high energy fractures after
traffic accidents are a devastating problem all over the world.
Thirteen bone injuries were among the 20 leading non-fatal
injuries sustained after road traffic accidents worldwide in
2002 [4], estimating 25 % of total health expenditures in
developed nations. Furthermore, a significant change in the
rank order of disability-adjusted years (DALYs, measuring
loss of health from disability) has been found from 1990 with
traffic injuries being the ninth cause and potentially becoming
the third cause in 2020. Disability frequently associates bone
healing fracture-related problems such as nonunion, at a rough
5 %–10 % rate. Delayed unions and nonunions after fracture
may relate to biomechanical factors that can be solved through
modifications of surgical technique, but the bone capability to
consolidate through regeneration may be compromised when
insufficient osteogenic reaction is observed in the fracture
callus, and an atrophic nonunion may develop. In those cases,
and provided vascular status and skin coverage are preserved
or recovered, biological potential for osteogenesis relying on
osteoprogenitor cell lines determines adequate healing. In the
United Kingdom, 850,000 new fractures are seen in a year, but
the overall regional nonunion incidence rate has been reported
in 18.9/100,000 population/year [7].
Osteoporosis-related fractures also require bone defect fill-
ing and structural support, and this epidemy in industrialized
countries is especially aggressive in Northern Europe, where
46.4 % of females over 65 are predicted to have a fragility
fracture (proximal femur, proximal humerus, distal radius,
vertebral bodies) [8], but also in Southern Europe [9], where
some of these are associated to complications with trabecular
compression and derived bone defects, but also related to
suboptimum healing potential. Metaphyseal osteoporotic frac-
ture may then result in poor fixation with secondary displace-
ment of internal fixation devices in spite of blocking screws
and other developments. In case of diaphyseal osteoporotic
fracture, decreased cortical thickness and increased canal di-
ameter also may derive into delayed consolidation or non-
union. In the specific case of periprosthetic fractures, usually
metaphyseal and/or diaphyseal, thin sclerotic bone supporting
the implant may also find difficulties to complete consolida-
tion. A decreased number of osteoprogenitors are associated
with advanced age where osteoporosis peaks, could be the
underlying cause and may benefit from future regenerative
solutions. All these circumstances are potential applications
that may be the case for future trials.
Other conditions where bone collapse occurs, with limited
bone regeneration capabilities such as primary or secondary
bone osteonecrosis frequently associated with avascular ne-
crosis or corticotherapy, have long been the case of cell
therapy approaches. Current solutions and options, in different
patient categories and underlying diseases, are also the case
for opportunities of basic and clinical research, as the efficacy
is highly variable.
Decreased biological capabilities in the injured or diseased
bone are the most interesting therapeutic targets for advanced
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bone healing augmentation techniques. However, to progress
towards clinical application, in any of the hypotheses, preclin-
ical data and regulatory approvals are needed and will be
discussed in the following sections.
Bone cell therapy: what preclinical studies are needed
Bone cell therapies have been proposed as alternatives to bone
grafting, in whichmesenchymal cells in the early phases of the
osteogenic line are transferred to the bone healing impairment,
alone or with a biomaterial scaffold. Unrestricted or at least
larger availability than autograft, higher cellular concentra-
tion, shorter surgical time and decreased associated morbidity
are some of their major advantages.
Different cell-based solutions have been proposed, with
different cell origins and technical specifications to prepare
the final cellular product that will be implanted where bone
regeneration is required. Solid preclinical data, adjusted to the
cell product and the clinical indication, are needed to launch
clinical trials, in the scope of obtaining the required authori-
zation from regulators.
To submit to the regulatory authority and thus to enter into
clinical trials, the researcher needs to prove that the cell
product under investigation, or investigation medicinal prod-
uct (IMP), complies with the quality standards that are re-
quested by the medicines legislation. The documentation
about standardization of the cell product that will be implanted
needs to be prepared by the producer, which is in many cases
the unit receiving the material from the orthopaedic surgeon
after obtaining it in surgery (in case of bone marrow, the
haematology units with capability to extract the cells and
eventually expand or manipulate those). But the research team
needs to support the file with preclinical data, both in vitro and
in vivo, that prove the safety of the procedures to the cells, the
safety to the host receiving those cells, the efficacy of these
cells to produce bone (or cartilage, or desired tissue) in the
laboratory, and the efficacy of these cells to produce bone in
the host. Those aspects need to be supported by in vitro tests
with the cells in culture, and in vivo tests usually in related
animal models.
Safety of cell products needs to be clarified from
manufacturing standards based on the Good Manufacturing
Practices (GMP) European regulation [10]. Similar studies to
conventional drugs are required to comply with the regulation,
from in vitro testing to safety proved in animals. This includes
general studies on pharmacological safety such as repeated
dose toxicity (addressing general toxicity), reproductive tox-
icity (ensuring the potential harm in gonads), and carcinoge-
nicity (confirming that no cell instability causes
carcinogenetic uncontrolled development). However, living
products such as those used in cell therapy raise concerns
about potential safety issues after stimulated expansion, even
in autologous cells. Therefore, safety issues require more
knowledge about its mode of action. The persistence of cells
in different sites where potential tumour formation could
happen may require tracing the cells implanted in animals to
clarify cell biodistribution and the potential for ectopic en-
graftment. However, the ultimate risk assessment (promoted
by the EuropeanMedicine Agency (EMA)with Guidelines on
Risk-based Approaches [11]) requires human phase I/IIa clin-
ical studies to further confirm the risks related to a certain cell
product are not increased. Finally, only clinical studies will be
capable of confirming those issues.
Efficacy to obtain bone regeneration in preclinical models
is also required to justify the use of a certain cell product in
clinical trials. If the cells to be implanted are not capable of
producing in vitro and in vivo bone regeneration, it would not
be realistic to implant those in patients. Therefore, cell differ-
entiation and mineralization are required as a preclinical proof
of efficacy to further progress towards the clinical application.
Safety, feasibility and efficacy end-points in clinical trials
When preclinical studies are available and provide enough
safety and efficacy data to support the start of clinical research
in humans, clinical trials need to be designed to clinically
confirm that the defined cell product is safe and efficacious
in well-controlled groups of patients and indications. There-
fore, the end-points of this research need to be clearly assigned
in coherence with the available preclinical data.
The first step will be to confirm the safety of the product as
well as to assess the feasibility of the proposed surgical
procedure and technical practicalities. Therefore, one or sev-
eral small-scale trials with safety and feasibility objectives will
be first planned before a larger, confirmatory, efficacy and
safety trial could be performed.
In order to decide on safety end points to be chosen, the
investigators should address different sources of complica-
tions: the potential problems of the technique itself and prob-
lems attributed to the product, either at the local level or
causing systemic complications. With regards to discard po-
tential systemic problems, the time of assessment should be
longer in order to be reasonably sure about the absence of
dissemination and proliferation of the cell products outside
their intended site of action.
The assessment of feasibility in a small-size trial is also
crucial to ensure the success of the trial, as well as to stan-
dardize techniques and devices as much as needed, in case
several surgeons and clinical sites are to be involved.
Efficacy end-points will depend on the disease to be treated
and will include clinical outcome evaluation, both objective
and subjective. In bone regenerative therapies, these include
bone imaging, patient assessment of function, pain and daily
activities, as well as frequently taking advantage of other
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available scores and questionnaires. It is acceptable to choose
imaging parameters as the principal endpoint in regenerative
therapy, but secondary efficacy end points related to function-
ality are also required to support the clinical outcomes of the
study.
Investigator driven clinical trials (IDCT) in advanced
therapy medicinal products (ATMP)
Advanced therapy medicinal products is a regulatory term
used to designate a group of special biological therapies that
are regulated under the medicines legislation and include gene
therapy, cell therapy, and tissue engineered products either
alone or combined with medical devices (Table 1).
As mentioned before, therapies based on cell and tissue
engineered products are being developed mainly by academic
investigators or groups in a non-commercial setting. A recent
revision of clinical trials with ATMP [12] revised the 318
distinct clinical trials authorised in the EU in the period
2004–2010, involving 250 individual ATMPs, and found that
the majority of them were sponsored by either academia
(50 %) or charitable organizations (10 %). Of note, the re-
maining CT sponsored by commercial entities involve mainly
small and medium enterprises or non-large pharmaceutical
companies.
Unfortunately, the organization and execution of a clinical
trial with medicines is a complex task that bears a heavy
burden of legal, regulatory, financial and organizational re-
quirements. Performing a clinical trial with ATMPs implies an
extraordinary effort, especially when driven by academic,
independent investigators willing to pursue the clinical re-
search of a cell product.
Regulation of clinical trials is well justified in order to give
public guarantee of protection of patient’s rights and ensure
the credibility of the results. Nevertheless, many of the proce-
dures established in clinical trial regulation were born to
regulate the activities performed by pharmaceutical compa-
nies during the clinical development of new medicines with
the intention to obtain a marketing authorisation, and they are
dysfunctional in hospital or academic settings. This is a source
of concern as it jeopardises the performance of independent
clinical research, which is essential to answer relevant public
health questions that are not in the agenda of pharmaceutical
companies. The disproportionate administrative charges
placed to an academic or hospital based research become even
more apparent in the case where the investigated intervention
is the potential clinical use of cell products prepared in hospi-
tal and not expected to be marketed.
When the investigator plans a clinical research with a cell
product, one of the first questions should be the regulatory
classification of the product. A therapeutic product consisting
of cells or tissues could be regulated, depending on the charac-
teristics of the product, either by the Tissues and Cells Directive
(Directive 2004/23/EC) or by the Advanced Therapies Medic-
inal Products (ATMPs) Regulation (Regulation 1394/2007)
[13]. The distinction between both types of products is relevant
because it implies different administrative procedures to com-
ply with. Nevertheless, it is not always easy to determine in
which category a specific product falls. In some cases, it will be
necessary to obtain a classification by the European Committee
of Advanced Therapies (CAT) or to revise previous decisions
on similar products released by this Committee.
The ATMP regulation establishes that a product will be an
ATMP if it is a gene therapy, somatic cell therapy, or tissue
engineered product, as defined in Table 1. In this definition,
the concept of “substantial manipulation” of the cells becomes
critical, as it determines if the product will be regulated as a
medicine (an ATMP) or not. The Directive 2001/83/EC [14]
contains the list of what is considered not to be a “substantial
manipulation” and it includes procedures such as irradiation,
concentration or cryopreservation. On the contrary, any cell
expansion will always be considered as a “substantial manip-
ulation” and therefore all products resulting from cell expan-
sion will be considered as ATMP.
In addition, non-substantially manipulated cells or tissues,
when they are not used for the same essential function or
functions in the recipient as in the donor, will also be consid-
ered as ATMP. This is why the CAT has classified cases of
non-manipulated cells as the autologous bonemarrow-derived
progenitor cells intended for treatment of patients with myo-
cardial infarction as ATMP, or even concentrates of autolo-
gous bone marrow intended for the increase of new bone
formation in a critical area of atrophic non-union.
The ATMP Regulation determines that medicinal products
classified as ATMPs, when applying for a marketing
Table 1 Medicinal products for human use considered advanced therapy
medicinal products (ATMPs) in the European Regulation
Regulation (EC) No 1394/2007 of the European Parliament and of the
Council of 13 November 2007 on advanced therapy medicinal products
and amending Directive 2001/83/EC and Regulation (EC) No 726/2004
Advanced therapy medicinal products (ATMPs):
— a gene therapy medicinal product
— a somatic cell therapy medicinal product:
• contains or consists of cells or tissues that have been subject to substantial manipulation
so that biological characteristics, physiological functions or structural properties relevant
for the intended clinical use have been altered, or of cells or tissues that are not intended
to be used for the same essential function(s) in the recipient and the donor
• is administered to human beings with a view to treating, preventing or diagnosing a
disease through the pharmacological, immunological or metabolic action of its cells
or tissues.
— a tissue engineered product, combined with a medical device:
• contains or consists of engineered cells or tissues, and
• is presented as having properties for, or is used in or administered to human beings
with a view to regenerating, repairing or replacing a human tissue.
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authorisation, shall be regulated under the centralised Euro-
pean Marketing Authorisation procedure. The marketing au-
thorisation will then be granted by the European Commission,
following assessment by the EMA relevant scientific commit-
tees (CAT and CHMP). Nevertheless, this regulation em-
powers member states (MS) to authorise hospitals, on a na-
tional basis, the use of ATMPs in the absence of a marketing
authorisation under the so-called hospital exemption clause
(article 28 of the ATMP Regulation). The hospital exemption
is applicable to all ATMPs that are prepared on a non-routine
basis, prepared according to specific quality standards (equiv-
alent to those for ATMPs with a centralised marketing autho-
risation), used within the same country, used in a hospital,
used under the exclusive responsibility of a medical practi-
tioner, and complying with an individual medical prescription
for a custom-made product for an individual patient.
The hospital exemption is a very good provision to allow
the use in hospitals of some non-commercial cell products that
have enough scientific data to support its therapeutic use.
However, a similar provision or exemption has not been
implemented for clinical research; the regulatory requirements
are the same for products under a commercial development
pathway than for products being investigated in the academic
or hospital environment without commercial intentions, with a
final aim to just give scientific support to its use under the
hospital exemption. This is even more striking if we realize
that the academic research accounts for a very high proportion
of the ATMP research and development.
Taking into account the complexity of clinical trials with
ATMP, we think it is useful to share information and results
about regulatory experiences of academic researchers, with
the aim to facilitate the organization and performance of future
clinical trials by other researchers.
Before launching the trial: authorization by regulators
and research ethics committees
The performance of a clinical trial is subject to several
international ethical codes and recommendations as well
as to local legislations. The need to obtain the free and
informed consent of any participant in the trial before
any procedure and the need of previous approval of the
whole project by a research ethics committee (REC) are
both well-recognized obligations that are contained in
international rules such as The Helsinki Declaration or
the Council of Europe Additional Protocol. Those doc-
uments should be known and fully respected by all
clinical researchers.
As far as the legislation is concerned, all member states of
the EU have national legislation establishing that the perfor-
mance of clinical trials with medicines are subject to a previ-
ous authorisation by a national competent authority (NCA).
Relevant NCAs in Europe, participating in the EU FP7-
REBORNE project, are listed in Table 2. In 2001, a first
European Clinical Trials Directive (Directive 2001/83/EC)
[14] was published in order to establish common principles
and harmonised procedures to all member states. The CT
Directive will be soon repealed and a new piece of European
legislation will enter into force. Both the European Parliament
and the EU Council agreed at the end of 2013 on a new
European Clinical Trial Regulation. Even with this new step
forward towards a common and streamlined regulation of
clinical trials in the EU, the competence for clinical trials
approval will remain at the national level.
The current CT Directive, as well as the different national
European legislations, define a clinical trial as “any systematic
study of medicinal products in human subjects whether in
patients or non-patient volunteers in order to discover or verify
the effects of and/or identify any adverse reaction to investi-
gational products, and/or study their absorption, distribution,
metabolism and excretion in order to ascertain the efficacy and
safety of the products”. This is a very wide definition that
includes any investigation with medicines, with the only ex-
ception of a pure observational study using an authorised
medicine. Therefore, academic orthopaedic clinical trials
targeting bone regeneration by the means of advanced therapy
medicinal products are subject to authorisation by the national
competent authority of the country (or countries) where the
trial takes place.
Table 2 National competent au-
thorities (NCA) or medicines
agencies in the participant coun-
tries in the REBORNE project
Country NCA Website
Italy Italian Medicines Agency http://www.agenziafarmaco.gov.it/
France National Agency for the Safety of Medicine
and Health Products
http://www.ansm.sante.fr/
Spain Spanish Agency for Medicines and Health Products http://www.aemps.gob.es/
Germany Paul Ehrlich Institute http://www.pei.de/
Belgium Federal Agency for Medicines and Health Products http://www.fagg-afmps.be/
Norway Norwegian Medicines Agency http://www.legemiddelverket.no/
Netherlands Medicines Evaluation Board http://www.cbg-meb.nl/
Romania National Medicines and Medical Devices Agency http://www.anm.ro/
International Orthopaedics (SICOT) (2014) 38:1803–1809 1807
Procedure for clinical trial authorisation by NCAs
Multinational clinical trial applications are assessed by NCAs
and RECs from each participating country independently. No
clinical trial may start in any country until both regulatory
approval and ethics committee positive opinion are available.
Usually, a third requirement is also necessary, which is a
contract or economical agreement between the sponsor and
investigators and trial sites.
Before submitting an application to any of these bodies, the
investigator or the applicant should obtain a unique EudraCT
number from the EudraCT Community Clinical Trial System
[15], which identifies the protocol for a trial and whether it is
conducted at a single site or at multiple sites in one or more
European member states.
The core submission package to the NCAs is the same in all
countries. It should include a cover letter, the EudraCT num-
ber, the application form, the protocol, the investigator’s bro-
chure, the investigational medicinal product dossier (IMPD)
and the simplified IMPD. However, each country has its own
submission and evaluation particularities, which may require
specific documents, additional steps in the regulatory proce-
dure as well as additional competent authorities involved in
the process. This type of assessment generates a lot of work to
organise a multinational trial in the EU, and even runs into a
risk of divergent decisions (approval, conditional approval, or
refusal) for the same clinical trial in different MS.
Differences are even greater for the RECs submissions, as
the procedure for ethics committee approval is different in each
MS and even between different RECs in the same country.
Generally, there can be a central ethics committee, regional
ethics committees and/or local/institutional ethics committees.
There are currently about 1,000 RECs in Europe [16].
RECs should consider several aspects when preparing an
opinion, such as the relevance of the clinical trial and the trial
design, whether the evaluation of the anticipated benefits and
risk is satisfactory, the protocol, the suitability of the investi-
gator and supporting staff, the investigator’s brochure, the
quality of the facilities where the clinical trial would take
place, the adequacy and completeness of the written informa-
tion to be given and the procedure to be followed for the
purpose of obtaining informed consent, provision for indem-
nity or compensation in the event of injury or death attribut-
able to a clinical trial, as well as any insurance or indemnity to
cover the liability of the investigator and sponsor, and the
arrangements for the recruitment of subjects.
In spite of this common approach for NCAs and RECs, the
investigator will be obliged to find the specific instructions on
what and how to submit to all concerned NCAs and RECs, as
well as pay the different fees that are requested. Fortunately, it
is rather common that both, the RECs and the NCAs, accept
requests for fee waivers or fee discounts in case of non-
commercial trials, rare diseases, ATMP or other explicit con-
ditions that could be present in these orthopaedic trials.
In summary, a substantial and experienced support is needed
to deal with multisite or multinational trial approvals and this
should be carefully considered in the trial budget and planning.
The European regulatory pathway in bone regeneration
The EU Heads of Medicines Agencies (HMA) established a
system called the voluntary harmonised procedure (VHP).
This system allows a joint assessment of a clinical trial by
the concerned authorities, harmonising the procedures and the
decision-making process to ensure the protection of partici-
pants as well as the scientific value of trials in the EU [17].
Even through voluntary harmonised procedures, each national
competent authority remains responsible for the approval of
the clinical trial application in its own country; therefore the
VHP takes place before the initial phase of the national
process.
The procedure started in 2009 and has been successful, as
shown by the increase of multinational trials using this method
as well as the future formalisation of this approach in the new
European regulation. According to VHP statistics, only 10 %
of the trials following this approach are non-commercial trials,
which could suggest this is an unknown or non-attractive
pathway to the academic investigators. Our group has used a
VHP procedure for a multicentric, multinational cell therapy
trial conducted in four member states (ORTHO 2 trial,
EudraCT2012-002010-39) and found several advantages in
comparison with pure national approvals.
The first positive result from the VHP is a direct consequence
of a single common assessment being done by all European
NCAs in a joint exercise, namely, the obligation of the NCAs
to agree on the distinction of what is “needed to know” from
what is just “interesting to know” before a trial is approved. We
think that NCAs probably coincide on what needs to be request-
ed before allowing a product to be marketed, but in our experi-
ence there is some room for differences betweenNCAs about the
level of requirements before approving a clinical trial (ie. docu-
mentation about the quality of the ATMP product or preclinical
package to support safety or preclinical data in animal models
supporting efficacy in a specific human condition).
The second positive result from our experience is the demon-
stration that a group of clinical researchers could join together in
a single multicenter multinational trial intended to provide com-
mon evidence about a potential clinical use in bone regeneration,
using an ATMP product from academic production centres as-
sociated with the different clinical sites, in a model of research
that resembles future therapeutic use under the hospital
exemption.
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Conclusions
A substantial interest and development of bone cell therapy can
be found in many orthopaedic surgeons and departments. Most
specialists are convinced that bone regeneration may be a good
opportunity to help our patients and evolve towards a more
biological approach of orthopaedic surgery and traumatology.
In reviewing the current epidemiology of musculoskeletal prob-
lems, different hypothesis can be identified. Better definition of
patients and diagnoses that may become therapeutic targets of
these advanced therapies is required. But before bone regenera-
tion therapies can be adequately applied to the general popula-
tion, safety and efficacy issues must be solved in the laboratory,
and clinical trials must be conducted to confirm the foreseen
benefit in specific patient groups. This risk/benefit assessment is
not yet available for most proposals, and significant opportuni-
ties to perform clinical trials on cell therapy can be found by
Orthopaedic surgeons with interest in bone regeneration.
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